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            Nowadays we have tremendous amount of genetic data needing to be 
interpreted. Somatic mutations, copy number variations and methylation are 
example of the genetics data we are dealing with. Discovering driver mutations 
from these combined data types is challenging. Mutations are unpredictable and 
have broad heterogeneity, which makes our goal hard to accomplish. Many 
methods have been proposed to solve the mystery of genetics of cancer. In this 
project we manipulate those above mentioned genetics data types and choose to 
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use and modified an existing method utilizing Markov Chain Monte Carlo 
(MCMC). The method introduced two properties, coverage and exclusivity. We 
obtained the data from The Cancer Genome Atlas (TCGA). We used MCMC 
method with three cancer types: Glioblastoma Multiform (GBM) with 214 patients, 
Breast Invasive Carcinoma (BRCA) with 474 patients and Colon 
Adenocarcinoma (COAD) with 233 patients.
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Chapter 1 
Introduction 
            In this work we aim at computational discovery of driver mutations that 
play a major rule in cancer progression and distinguish them from passenger 
mutations that are present in cancer cells but do not contribute to the disease. 
We start with introducing relevant biological background, and then move to 
computational methods for processing cancer mutation data and algorithms for 
discovering driver mutations. 
The Genetic Roots of Cancer  
            Cancer is a term given to any disease in which abnormal cells divide 
indefinitely and have the ability to invade other tissues. The American Cancer 
Society estimates the diagnosis of 1,660,290	  new cases of cancer and that the 
later will account for 580,350 deaths in 2013 (American Cancer Society, 2013). 
Cancer is a complex and heterogeneous disease to which all body organs and 
tissues are susceptible. It is believed to be a genetic disease of cells. 
Carcinogenesis typically involves the following chain of mutations that 
deregulates cellular proliferation; m1: inactivation of a tumor suppressor gene 
results in cell proliferation, m2: mutation(s) that inactivates a DNA repair 
pathway, m3: a mutation in a proto-oncogene that leads to the generation of an 
oncogene and m4: mutation(s) that inactivates additional tumor suppressor 
genes resulting in cancerous proliferation (reviewed in Cornelisse & Devilee). 
Normal genes in the cell that control cellular proliferation are called proto-
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oncogenes, which can be mutated to form oncogenes that promote uncontrolled 
cellular proliferation. Such mutations are considered dominant or gain of function 
mutations. Therefore, one mutated copy of the gene is enough to promote 
cancer. In contrast, tumor suppressor genes are those encoding proteins that 
normally inhibit tumor formation inhibiting cellular proliferation. These mutations 
are recessive or loss of function mutations where loss of both copies of a gene is 
required to inactivate a tumor suppressor gene (Hanahan & Weinberg, 2000). 
Ongoing research over the past years have revealed that cancer occurs as a 
consequence of a hereditary mutation or an environmentally induced mutation 
with or without genetic-environmental interaction (Knudson, 2002). A change in 
the genome of a particular cell in the form of a mutation could be of various 
types. These include: point mutations which causes amino acid substitutions that 
either truncate a protein product or scramble it’s sequence; chromosomal 
imbalances or instability resulting in amplification, overexpression or loss of a 
gene; epigenetic modifications of the DNA of which is the most important is DNA 
methylation (Bertram, 2000).  
The Role of Somatic Mutations, Copy Number Alterations and DNA 
Methylation in Cancer 
            The cancer cell is like any other cell that constitutes the human body in 
being a direct descendent through mitotic cell division of the fertilized egg from 
which the human being has developed. However, a cancer cell as well as most 
normal cells acquire a number of alterations in the DNA sequence from it’s 
progenitor fertilized egg. These alterations are collectively named somatic 
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mutations to distinguish them from germline mutations that are passed from 
parents to offspring (Stratton et al., 2009). It is thought that somatic mutations 
occur in the genomes of normal cells through successive round of cell division 
during development in utero and during regeneration of body tissues in postnatal 
life. Moreover, the DNA in normal cells is susceptible to continuous damage by 
endogenous and exogenous mutagens. Most of this damage is repaired except 
for a small fraction that may be converted into fixed mutations, which may confer 
a selective growth advantage leading to clonal proliferation of these cancerous 
cells (Stratton, 2011). There are several distinct classes of somatic mutations in 
cancer cell genomes including substitutions of one base by another; insertion or 
deletion of small or large DNA segments; rearrangements in which a segment of 
DNA is broken and relocated to elsewhere in the genome; changes in the copy 
number of DNA segments; epigenetic alterations that are stably inherited through 
mitotic DNA replication. Somatic copy number alterations (SCNAs, distinguished 
from germline copy number variations, CNVs) are structurally variant regions with 
either gains or losses of genomic DNA. They play a major role in cancer 
development through the amplification of oncogenes or the deletion of tumor 
suppressor genes.  
            Epigenetic marks are defined as modifications of the DNA and associated 
proteins that alter gene expression independent of alterations in the DNA 
sequence. The four main epigenetic modifications are DNA methylation, histone 
modification, chromatin remodeling and RNA-mediated targeting. In addition, 
epigenetic regulation is an essential phenomenon for proper development and 
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cellular differentiation in normal human tissues. The well known and best studied 
epigenetic modification is DNA methylation at the carbon 5 of cytosine residues 
that precede guanines, refereed to as CpG dinucleotides, by DNA 
methyltransferases (DNMTs). 70-80% of cytosines in the genome of normal cells 
are methylated. Furthermore, areas of the genome with high concentration of 
CpGs are called CpG islands and are located in the promoter region of 50% of 
human genes, thus these areas are mostly unmethylated (Huidobro et al., 2013). 
Earlier studies on gene expression and DNA methylation have shown an 
interaction between cancer and epigenetics.  Promoter hypermethylation leading 
to transcriptional silencing and global hypomethylation are of the most 
characterized epigenetic changes in human cancers (Dawson & Kouzarides, 
2012). Therefore, we now know that growth-promoting genes are activated 
through hypomethylation in tumors. Moreover, tumor suppressor genes silencing 
have been found to be linked to promoter hypermethylation (reviewed in 
Iacobuzio-Donahue, 2009). Given the plasticity and heritability nature of 
epigenetic modifications, DNA methylation is ideally suited to the processes of 
clonal variation and clonal inheritance, which are required for the transformation 
of a normal cell into a malignant cell.  
“Driver” vs “Passenger” Genes 
            Cancer genomes carry two biological classes of somatic mutations, which 
are driver and passenger mutations depending on the corresponding nature of 
this mutation to cancer development (Stratton et al., 2009). Driver mutations 
provide the neoplastic clone with growth advantage. Therefore, they allow this 
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neoplastic clone to proliferate more than normal cells from the same tissue, 
invade the surrounding tissues and in most cases permit metastasis. These 
mutations reside by definition in a subset of genes known as “cancer genes”. 
Given that, the number of mutated cancer genes is reflected by the number of 
driver mutations in a cancer cell, thus the required dysregulated cellular 
biological processes to convert a normal cell into a cancer clone. On the other 
hand, passenger mutations, which in most cases constitute the majority of 
mutations, are those that do not confer a growth advantage.  Instead, it is thought 
that these mutations were present in the ancestor of the cancer cell when it 
acquired any of it’s driver mutations ( Stratton, 2011). As a result, these 
passenger mutations arise from mutational exposures, genome instability or from 
the increased cell division and doubling that give rise to a clinically detectable 
cancer from a single transformed cell (Haber & Settleman, 2007). Having both 
driver and passenger mutations in the cancer genome makes it challenging to 
distinguish them from each other, hence discovering the genes that play an 
essential role in tumorigenesis.  
Analysis of cancer samples using high-throughput methods 
            During the past decades, there have been major advances in 
characterizing cancer genomes through first generation sequencing (also known 
as Sanger sequencing). Alternatively, next generation sequencing (NGS) has 
been developed over the past 7 years with higher throughput and increased 
sensitivity derived from it’s deep coverage. Moreover, the application of NGS has 
tremendously decreased the time and cost required for data generation ( 
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reviewed in Dong & Wang, 2012). However, the availability of large data sets 
from these techniques implicates a number of challenges. One challenge is the 
ability to distinguish “driver mutations” that are important for cancer development 
from “passenger mutation” that have accumulated in somatic cells but are not of 
an importance in cancer development. One standard approach for identifying 
“driver mutations” is to test for genes that are recurrently mutated in a large 
number of cancer genomes. This approach has been useful in identifying only a 
subset of “driver mutations” due to the extensive mutational heterogeneity not 
only among different cancer types but also among individuals with the same 
tumor type (Vandin, Upfal & Raphael, 2012). This brings is to another challenge 
that arises from the generation of tremendous amount of data, which is the need 
of computational and algorithmic tools for the analysis of the growing data sets 
from NGS of cancer genomes.  
            The data generated from these cancer genome characterization efforts 
have put the need for data accessibility and in depth comparative analyses of 
different cancer types. The Cancer Genome Atlas (TCGA) is a perfect resource 
for this purpose, providing complete catalogs of the genomic alterations in a 
collection of patient samples that have been characterized in a cancer-type 
specific manner (Chin et al., 2011). 
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Existing Computational Methods for the Identification of Driver Genes 
           There are several methods to discover driver mutations. Below, we outline 
two existing methods in order to give a background on some existing approaches 
for discovering driver mutations. The first method was proposed in (Ciriello, 
Cerami, & Sander, 2012) and the second method was initially introduced by 
(Vandin, Upfal, & Raphael, 2011). The last method is the method we used in this 
work and it is introduced by (Vandin, Upfal, & Raphael, 2012). 
I. Mutual exclusivity analysis to identify oncogenic network modules 
The algorithm consists of five steps:  
1. Building a binary matrix of genes that has been evaluated as significant or 
not significant. The gene is considered significant if it is recurrently mutated. 
Moreover, genes that recurrently experience a high level of amplification or 
homozygote deletion proportional to their expression are considered significant 
as well.  
2. Categorizing filtered genes and pairing them while using previous 
knowledge of biological networks and pathways. 
3. Building a graph and connecting similar gene pairs.  
4. Extracting local fully connected sub graph clusters, which are most likely 
to have similar biological characteristics. 
5. Putting the extracted clusters through further filtration to confirm mutual 
exclusivity as well as excluding the possibility that these gene clusters have 
been constructed by chance. The Permutation Test is a test that permutes the 
genes, appeared in the original binary matrix, across the samples several times. 
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During permutation, edges are added and deleted, resulting in random modules. 
After calculating the p-value of about Q |whole set of edges| random generated 
modules, finding a low P-value makes the original cluster module unlikely to 
have been generated by chance.  
The filtered clusters are considered potential driver networks that initiate cancer 
(Ciriello, Cerami, & Sander, 2012). 
II. Heat diffusion   
            The aim of heat or fluid diffusion (Vandin, Upfal, & Raphael, 2011) is to 
extract sub-networks that contain highly mutated genes. Observing two highly 
mutated genes connected by a single low-degree node is of great interest. On 
the other hand, it is less interesting to have a single high-degree node 
connecting several highly mutated genes. The steps constituting the algorithm 
used to extract sub-networks are as follow: 
1. Diffuse heat to each mutated gene proportional to the frequency of 
mutation of a given gene. The heat then conducts through the edges for a 
certain period of time.  
2. Assign an influence measure between graphed gene pairs according to 
the heat distribution. A low-degree node will have small neighbors to diffuse the 
heat to; accordingly the nodes will remain hot. Alternately, high-degree nodes 
will have neighbors of any size to diffuse the heat to, and thus will not be able to 
keep their heat. 
3. Break the network into sub-networks according to the heat distribution and 
	  	   9	  
the score of the node (gene). A highly mutated gene that is present in a high 
number of patients has a higher score than a gene that is not frequently 
mutated. 
4. Evaluate these sub-networks statistically and assess the possibility of 
having similar sub-network by chance. 
III. De novo discovery of mutated driver pathways in cancer 
            The method proposed by (Vandin, Upfal, & Raphael, 2012) is based on 
two assumptions. The first assumption is that a statistically significant cancer 
pathway is likely to be perturbed to cause cancer, i.e., utilizing a genome-wide 
approach for screening a group of patients with the same cancer type will reveal 
the perturbation of a certain pathway in these patients. The second assumption 
is that one driver gene mutation in an important cancer pathway is enough to 
perturb the pathway (McCormick, 1999) (Vogelstein & Kinzler, 2004). 
Furthermore, given the rare and single pattern appearance of a driver mutation, 
we expect a mutually exclusive pattern of driver mutations (Chen-Hsiang, 2008).  
Markov chain Monte Carlo (MCMC) is the algorithm used to identify driver 
mutations using the above-mentioned assumptions in (Vandin, Upfal, & 
Raphael, 2012). The purpose of using (MCMC) is to find a set of mutated genes 
that both cover most of the patients (high coverage) and most of the covered 
patients have one gene mutated from that set (high exclusivity). The data used 
in MCMC was somatic mutation and copy number variations (CNVs) from 
TCGA. Details about using MCMC will be further mentioned in the materials and 
methods section. 
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Goal of the thesis 
           Our goal in this thesis is to discover driver mutations in cancer. We relied 
on the existing method described in (Vandin, Upfal, & Raphael, 2012). The main 
task was to apply the method to a broader set of data containing additional types 
of mutations. We included copy number alteration and methylation as additional 
types of mutations. 
           We used MCMC with small modifications in the parameters and data. The 
first modification is based on our insufficient knowledge of the number of cancer-
specific driver genes. We extended the method to include variable number of 
genes. Thus, we used MCMC to look for a set of driver genes between three and 
seven. The second modification is based on our desire to include copy number 
alterations (CNAs) and methylation in the data. Since somatic mutations are not 
the only cause of cancer, its use as a single type of mutations could mask other 
underlying causes of cancer. Given that CNAs and methylation contribute greatly 
to the onset of cancer, including them in the data will help in completing the 
underlying picture of cancer. 
            It is challenging to use somatic mutations, CNA and methylation as an 
input data. One of the reasons is that somatic mutations have variability in the 
mutated position of each gene mutated. Therefore, a much bigger data size is 
needed because of the possibility of two patients with the same mutated gene 
would have different mutation position. Another potential difficulty is the fact that 
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methylation is in the nucleotide level, which could complicate its comparison to 
somatic mutations even when disregarding the mutation position. Moreover, 
more than one gene could be included in the case of CNAs.  
     To use somatic mutations, CNAs and methylation at once, we focused on the 
genetic level by following certain rules: 
• We disregard the nucleotide position variations and only consider the 
gene name in somatic mutations. 
• In methylation, if a given position is abnormally methylated we consider 
that gene to be mutated. 
• In CNAs, any gene included in significant CNAs is considered mutated. 
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Materials and Methods 
1. Sources 
1.1 Somatic mutation data 
            We downloaded all available data in TCGA level 2 for Glioblastoma 
Multiforme (GBM), Breast Invasive Carcinoma (BRCA) and Colon 
Adenocarcinoma (COAD). TCGA does not have level 3 data available for 
somatic mutations. Therefore, although that would be the higher TCGA level 
having the most possible verified data, we had to use level 2. We gathered this 
TCGA data from the following sources: for GBM, the Broad Institute 
(http://broad.mit.edu/); for Breast Invasive Carcinoma, the Genome Institute 
(http://genome.wustl.edu/); and for Colon Adenocarcinoma, the Human Genome 
Sequencing Center or HGSC (https://www.hgsc.bcm.edu/). 
1.2 Copy number variation (CNV) data 
          We downloaded all available data in level 3 for Glioblastoma Multiform 
(GBM), Breast Invasive Carcinoma (BRCA) and Colon Adenocarcinoma (COAD). 
TCGA data on GBM was provided by the Memorial Sloan–Kettering Cancer 
Center (MSKCC), Harvard-Partners Center for Genetics and Genomics (Harvard 
Medical School), Broad Institute and Stanford University HudsonAlpha Institute 
for Biotechnology. TCGA copy number variation (CNV) data on BRCA and 
COAD was provided by the Broad Institute. 
1.3 Methylation data 
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            We downloaded all available data in level 3 for Glioblastoma Multiform 
(GBM), Breast Invasive Carcinoma (BRCA) and Colon Adenocarcinoma (COAD). 
TCGA data on GBM, BRCA and COAD was provided by USC Epigenome 
Center, University of Southern California. 
2. Filtering the data 
            Our target was to extract the genes’ “TCGA-barcode,” “Hugo-Symbol” 
and “Entrez-Gene_Id” (if available), and to collect these data into a file organized 
by columns in that order (Where the data is not available, we had to infer or 
deduce the required information). To reach that objective we went through 
several filtering processes, which are different for each data type. 
2.1 Filtering somatic mutation data 
            We downloaded mutation data as a Mutation Annotation Format (MAF), 
which has a lot of columns describing the samples. The only columns we utilized 
from this format were “Hugo_Symbol,” “Entrez_Gene_Id” and 
“Tumor_Sample_Barcode.” Using Unix “cut” command, I extracted these needed 
columns. Then we used AWK, a Unix based interpreter language, to reorder the 
columns to the required format for our data file. The TCGA barcode consists of 
the flowing information: “TCGA” as the initial tag followed by the tissue source 
type code, the participant code, sample code, portion code, plate code and finally 
the center code. We only used the portion consisting of the “TCGA” tag, the 
tissue source code type and the participant code; instead of writing a program I 
used regular expression to cut unwanted parts of the full TCGA barcode. In the 
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extracted table we found that some Entrez Gene Ids had a zero value, which 
does not match the Hugo Symbol and means there is lack of information for that 
Id. To deal with this situation, we developed 
“GeneSymbol_to_Entrez_converter.py,” a converter that uses a reference map to 
go through each line of our data file and check that each Hugo Symbol has a 
matching Entrez Gene Id. We downloaded the reference table that maps “Hugo-
Symbol” to “Entrez-gene-Id” from the HUGO Gene Nomenclature Committee 
(HGNC) to use in the “GeneSymbol_to_Entrez_converter.py”. Once each column 
in the file had the required information of “TCGA-barcode,” “Hugo-Symbol” and 
“Entrez-Gene_Id”, the somatic mutation data was ready to be merged with the 
other data with the same format. 
2.2 Filtering CNV data 
            The downloaded package for CNV includes the following files and folders: 
• CNV_SNP_Array folder. 
• FILE_SAMPLE_MAP.txt file. 
• METADATA folder. 
The “CNV_SNP_Array” folder has the data in multiple files with many lines to 
each file. Data files have the following header: 
• Sample: sample ID. 
• Chromosome: chromosome number. 
• Start: where the segment begins. 
• End: where the segment ends. 
	  	   15	  
• Num_Probes: Probes used in an each segment. 
• Segment Mean: if the segment mean is around zero, there is no loss or 
gain. If the segment is above zero, we can recognize a gain, and if the 
segment is less than zero, that indicates a loss.  
We needed to modify the data in order to have it ready to use we needed to do 
the following: 
2.2.1 Transforming the data to be binary 
            We wanted to use segment mean to decide if a given gene was included 
in the CNV. The obstacle is that the segment mean is not a 0 or 1 value. To get 0 
or 1 value, we calculated the mean and the standard deviation of each probe 
segment-mean occurring in all samples and extracted the abnormal segment-
means. We did not use the typical measurement of the segment mean 
mentioned above. Instead, we wanted to have a new cutoff value to decide if the 
segment had been repeated or lost. We decided to use the mean and the 
standard deviation as a cutoff value, so we first calculated the mean and the 
standard deviation of each probe segment-mean which occurred in all samples 
using,"CNV_FILES_Mean_SD_Calculator.py”, a program we wrote. We wanted 
to know how many patients were above 1, 2, 3 and 4 standard deviations in order 
to decide what the cutoff should be. "Calculate_How_many_Patients_above_1-2-
3-4_SD.py" calculates the number of samples above and under ‘X’ standard 
deviation. We choose 3SDs to be the cutoff as there were too many samples 
below 2SDs and few above 4SDs. We considered a specific probe segment-
mean a gain in copy number if it was above 3 standard deviations of the mean of 
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all segment-means of that specific probe in all samples. Likewise, we considered 
a specific probe segment-mean a loss in copy number if it was below 3 standard 
deviation of the mean of all segment-means of that specific probe in all samples. 
To make these calculations and extract the desired data, we used 
"Abnormal_CNV_Extractor.py,", which only extracts from each file the abnormal 
lines and copies them in a different directory. 
2.2.2 Converting gene beginnings and gene ends into gene names 
            The following rules were applied to decide whether the gene was inside 
or outside the segment: 
a) If the whole gene was inside the segment then we considered the copy 
number of that gene as a variant. 
b) If the whole segment was inside a gene we also considered the copy 
number of that gene as a variant.  
c) If 50% of the gene was inside the segment we considered the copy 
number of that gene as a variant.  
To achieve the conversion goal, we wrote 
"GenePostion_to_GeneName_Converter.py". This program goes through each 
line on each file and, depending on the beginning and the end of each line, 
converts it to Ensembl gene ID. This program needed a reference file containing 
the beginning and the end of each gene, which can be gotten from the Ensembl 
Genome Browser. 
2.2.3 Converting the Ensembl to Entrez and HUGO gene symbol 
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            Using the data table downloaded from the HUGO Gene Nomenclature 
Committee (HGNC) that contains Ensembl, Entrez and HUGO gene symbols, we 
wrote the "Ensembl_to_Entrez_GeneSymbol_converter.py" program to convert 
the Ensembl gene ID into desirable names. 
2.2.4 Mapping the sample ID to TCGA sample code 
            The downloaded data has an ID sample different from global TCGA 
barcode ID, which we want to unify. The downloaded folder has 
“FILE_SAMPLE_MAP.txt”, which maps the sample ID to the TCGA barcode ID. 
TCGA_Mapper.py is a program that maps the IDs and prints all files into a new 
folder with the required TCGA barcode. 
2.2.5 Organizing the desired file structure 
            After we got the required sample code, we wanted each column in the file 
to be formatted in the following order: TCGA barcode, Entrez ID and gene ID 
symbol. Instead of writing a new program code to organize the data this way, I 
wrote this code as a part of one of the previous programs. The final output is one 
file that has the above-mentioned columns in order, ready to be merged with 
other filtered data. 
2.3 Filtering methylation data 
The downloaded package for methylation data includes the following files and 
folders: 
• DNA_Methylation folder. 
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• FILE_SAMPLE_MAP.txt file. 
• METADATA folder. 
The “DNA_Methylation” folder has the data in multiple files and each file has 
many lines. Data files have the following header: 
TCGA Barcode   probe name    beta value   gene symbol    chromosome 
position. 
• TCGA barcode: sample ID.  
• Probe name: Probes used at each position. 
• Beta value: the intensity ratio. 
• Gene symbol: HUGO symbol. 
• Chromosome:  chromosome number.  
• Position: at what position in the chromosome.  
We needed to modify the data in order to have it ready to use we needed to do 
the following: 
2.3.1 Compare the methylation data to a reference 
            We needed to have a normal reference of beta value for each probe. We 
do not know if a position is methylated or unmethylated, but we know that when 
the beta value is close to zero it’s more likely to be unmethylated; also, the closer 
beta value is to one, the more likely it is to be methylated. The Gene Expression 
Omnibus (GEO) has data for a Genome-Wide Methylation Analysis containing 
data of normal patients for brain, breast and colon cancers among the data for 
abnormal patients. We used many programs to filter the data downloaded from 
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GEO. Using Unix commands, we cut the column that has data known to be 
normal patients’ samples for brain, breast or colon cancer. The methylated data 
in GEO per cancer type is scattered in different project files and we need them to 
be in one file to simplify the analysis and infer what normal status (methylated or 
unmethylated) of each probe position should be. “Methylation_files_joiner.py” is a 
program which joins the normal methylation columns from different GEO files into 
one file containing probe names and columns with beta values of normal patients 
with same tissue type. We have 5 normal methylated brain tissue data, 37 
normal methylated breast tissue data and 33 normal methylation colon tissue 
data. Each line in those data starts with the probe name and is followed by the 
beta value of each patient for that probe. We saw earlier the somatic mutation 
data has the following columns information; “TCGA-barcode,” “Hugo-Symbol” 
and “Entrez-Gene_Id” and we need the same information with methylation data. 
GEO has data table that maps each probe to the gene Entrez ID and the gene 
symbol ID and its synonyms. “Gene_Id_Synonyms_appender.py” is a program 
which uses GEO mapping table to map each probe name to gene Entrez ID and 
gene symbol ID, and adds the new two columns of the gene Entrez ID and gene 
symbol ID into the new file that has the data for normal beta values. 
2.3.2 Extracting the common probes between methylation data folders 
             Unify the probes in the raw data files. “DNA_Methylation” downloaded 
from TCGA has the raw methylated data in two files. The first file starts with “hu-
usc.edu__HumanMethylation450” and the second starts with “hu-
usc.edu__HumanMethylation27”. The HumanMethylation27 file has fewer probes 
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than HumanMethylation450 file. We wanted each probe in the sample file to have 
the normal reference beta value we created. All probes in HumanMethylation27 
file have a normal reference beta value, while HumanMethylation450 does not 
because the GEO that we extracted normal beta value from used the same 
probes and illumine platform as HumanMethylation27. We solved this in 4 steps 
a) Finding the common probes between HumanMethylation27 and the 
normal reference beta value file. 
“Common_Uncommon_Probes_Finder.py” is a program, which reads two 
files and outputs the uncommon and the common probes. We ran the two 
files and found out that all HumanMethylation27 file probes had a normal 
beta value. 
b) Finding the common probes between HumanMethylation450 file and the 
normal reference beta value file. We ran the two files and found out that 
there were 457,999 probes out of 485,578 probes within 
HumanMethylation450, which were not in the normal reference beta value 
file, so we need to get rid of the lines of extra probes. 
c) Finding the common probes between HumanMethylation27 and 
HumanMethylation450. “Common_Uncommon_Probes_Finder.py” read 
one file from HumanMethylation27 folder, one file from the normal 
reference beta value file and one from HumanMethylation450 folder, and 
then output the extra probes in HumanMethylation27 and the common 
ones in both files. We found all 27,579 probes in HumanMethylation27 in 
HumanMethylation450. 
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d) Deleting uncommon probes from all files existing in the 
HumanMethylation450 folder. We did not use any probe that existed in the 
HumanMethylation27 files but not in HumanMethylation450. So we wrote 
a program called “Unmatched_Probes_Deleter.py” to go through each 
HumanMethylation450 file and delete all 457,999 uncommon probes. 
By doing these steps, we have the same number of probes in the 
HumanMethylation27 and HumanMethylation450 folder files and a 
reference of normal beta values for each probe. 
2.3.3 Extracting abnormally methylated/unmethylated data 
            Having our probes in normal beta value matched to the probes in the 
TCGA data, we wanted to go through each probe of each patient and extract the 
abnormal methylated data. The purpose of this step was to have a reference 
data to decide whether a given position in a specific gene should be methylated 
or not. “MethStat.py” is a program for calculating the statistical summary for each 
probe. Calculated data includes the number of patients, the mean and standard 
deviation, the minimum, maximum and the skew. We need to have this 
information to establish the cutoff for methylated/unmethylated for each probe. 
Our first approach to analyzing the data was to use the mean and 2 SD; if the 
probe reading was 2 SD away from a normal reference probe, we considered the 
gene contained in that position methylated and it would be included in the 
abnormal methylated gene file. This approach did not work because it showed 
that most probes in all patients were methylated, which is unlikely to be true. We 
made another attempt using the minimum/maximum of the normal reference 
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instead. If the minimum normal beta value is above 0.75 and the patient beta 
value is below 0.25, then this patient’s gene is abnormally unmethylated. If the 
maximum normal beta value is below 0.25 and the patient beta value is above 
0.75, then this patient’s gene is abnormally methylated. 
“Meth_Analyzer_MinMax.py” uses the above-mentioned algorithm to extract the 
abnormal lines. The final output is one file that has the following columns “TCGA-
barcode,” “Hugo-Symbol” and “Entrez-Gene_Id” that are ready to be merged with 
other filtered data. 
3. Merging the filtered data (Somatic Mutation, CNV, Methylation) 
            We wanted to have one file of unified (filtered) genetic information about 
Somatic Mutation, CNV and Methylation containing the data from patients that 
fulfill all three categories. We didn’t want patients with missing information; in 
other words, in order for a patient to exist in our final filtered data, he/she must 
have a TCGA barcode in each of the Somatic Mutation, CNV and the Methylation 
filtered files. “Common_Patients_extractor.py” is a program that goes to each 
data file using the format “same column headers” and finds the common 
barcodes between the three filtered data. After that it goes through each file 
again and prints the lines with the common barcodes into one file. We have done 
this to the three cancer types: Glioblastoma Multiform (GBM) with 214 barcodes 
(patients), Breast Invasive Carcinoma (BRCA) with 474 barcodes (patients) and 
Colon Adenocarcinoma (COAD) with 233 barcodes (patients). Having done that, 
we were ready to use MCMC algorithm to extract driver genes for each cancer 
type. 
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4. Algorithm for discovering driver mutations   
4.1 Problem Description 
            To have a better understanding of the problem described in (Vandin et 
al., 2012), let 𝑃 = 𝑝 𝑝   ∈   𝑐𝑎𝑛𝑐𝑒𝑟  𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠  and 
𝐺 = {𝑔  |∃  𝑝 ∈ 𝑃 ∶   𝑔𝑒𝑛𝑒  𝑔  𝑖𝑠  𝑚𝑢𝑡𝑎𝑡𝑒𝑑  𝑖𝑛  𝑝}. Relation R from G to P is defined as 
follow: For all g,p ∈ G  ×P, g,p ∈ 𝑅  means g is either mutated, methylated or 
having a copy number alteration, and we use 𝑔  𝑅  p as a notation for the relation. 
Let Γ g =      p p ∈   P ∩ g  R  p}  denote the set of patients having gene g mutated. 
Let M= {M ⊆ G} and Γ(M) denotes the group of patients so that each has at least 
one gene in set M mutated, methylated or having a copy number alteration. Set 
M is considered mutually exclusive if each patient within this set has only one 
gene g mutated. For example let 𝑔𝑥  and 𝑔𝑦 be any two genes ∈  M, in this case set 
M is considered mutually exclusive if Γ 𝑔𝑥 ∩   Γ 𝑔𝑦 =   Ø. We wanted to have a 
mutually exclusive set M that also covers most of the patients. In other words 
they wanted to maximize Γ(M) such that M is mutually exclusive. However, this is 
computationally difficult. Furthermore, the rule of mutually exclusive is impractical 
to follow due to the presence of noise (passenger mutations) and measurement 
errors.  
4.2 Coverage and exclusivity maximization 
            In regard to solving the above-mentioned problem, (Vandin et al., 2012) 
proposed to modify the mutual exclusivity restriction for set M and consider Γ M   as a criterion. With the application of this modification, mutually exclusive 
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is now considered approximately exclusive in which most of the patients have no 
more than one gene mutated in M whereas the coverage is not changed in which 
the majority of patients have one or more genes mutated in M. Implementing this 
relaxation rule results in a trade off between exclusivity and coverage. Moreover 
it leads to a certain number of patients with coverage overlap, in which patients 
can have more than one gene in the set M mutated. The mathematical 
expression of the coverage overlap is: 
                                      𝜔 𝑀 = Γ g − |𝑔∈𝑀 Γ M |.  
Coverage overlap equation in words mean the summation of all set of patients 
that have gene g from set M mutated subtracted from the all patients with at least 
one gene in set M mutated.  For Example if our driver genes set is x y and z and 
we have a patient with those 3 genes mutated then 𝜔 𝑀 = 3− 1, which is the 
excess mutation above the required number of mutation. In other words 𝜔 𝑀  is 
number of mutations above one per patient. 
            Coverage overlap is addressed by subtracting it from the coverage Γ M   and have the weight 𝑊(𝑀): 
𝑊 𝑀 = Γ M − 𝜔 𝑀 . 
                                            𝑊 𝑀 = 2   Γ M − Γ g𝑔∈𝑀 . 
The penalty ω(M) = 0 when M is mutually exclusive. Now that we have a defined 
weight, the problem is to maximize the weight 𝑊 𝑀  by finding the appropriate 
gene set M. 
	  	   25	  
4.3 The Metropolis-Hastings algorithm 
            Metropolis-Hastings algorithm (Metropolis, 1953) (Hastings, 1970) is a 
well-known established algorithm. It has been used in different applications as 
well as to solve the above-described problem. We used Metropolis-Hastings 
algorithm with k = number of the genes in the set and n = number of iteration. 
4.4 Size changing algorithm 
       We improved the algorithm by incorporating variability in set sizes. In each 
iteration there is a chance that instead of going through the rest of the algorithm, 
we change the number of the genes in the set Mi by removing or adding genes 
from gene set G.  The variability of the set size accomplished is as specified 
below. 
Pseudo code Description 
Initialization: 
 M1 = RANDOMSET(k,G) 
 
Iteration: 
   For i = 1 to n 
      r = RANDOMGENE(G). 
      s = RANDOMGENE(Mi). 
       𝑀!!!! =   𝑀! − 𝑠 + 𝑟. 
     𝑊! =   𝑐𝑊 𝑀!!!! − 𝑐𝑊(𝑀!). 
     p = min[1, 𝑒!!]. 
     𝑀!!! =   𝑀!!!!   𝑤𝑖𝑡ℎ    𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑝 . 
     Otherwise Mi+1 = Mi. 
 
From the whole gene set G choose k genes randomly to be the 
starting gene set M1. 
 
 
Randomly choose gene r from the whole gene set G. 
Randomly choose gene s from the current gene set Mi. 
Replace gene s in set Mi with gene r as a new candidate set. 
Calculate Wi by replacing gene s in set Mi with gene r. 
p is Min between 1 and the weight difference Wi. 
The more p the more likely 𝑀!!!to be equal 𝑀!!!!. 
Go to next iteration with the same set Mi if 𝑀!!!! fail not 
replace Mi. 
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Suppose kmax is the maximum number of gene k inside set M and kmin is the 
minimum number of gene k at any given set Mi. 
 
Pseudo code Description 
Initialization: 
 M1 = RANDOMSET(k,G) 
 
Iteration: 
For i = 1 to n 
Boolean=FlipTheCoin() 
if (Boolean==0) 
   Continue with Metropolis-Hastings algorithm. 
else:        
     k = RANDOMNUMBER( kmax,,  kmin)  
     𝑖𝑓  (𝑘 > |𝑀!|) 
         𝑤ℎ𝑖𝑙𝑒  (𝑘 > |𝑀!|)  
             𝑟 = RANDOMGENE(G)  
             𝑀! =   𝑀! + 𝑟 
     else 
             𝑤ℎ𝑖𝑙𝑒  (𝑘 < |𝑀!|)  
           𝑟 = RANDOMGENE(𝑀!)  
           𝑀! =   𝑀! − 𝑟           𝑊! =   𝑐𝑊 𝑀! − 𝑐𝑊(𝑀!). 
    p = min[1, 𝑒!!]. 
    𝑀!!! =   𝑀!   𝑤𝑖𝑡ℎ    𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑝 . 
    Otherwise Mi+1 = Mi. 
   
From the whole gene set G choose k genes randomly 
to be the starting gene set M1. 
 
 
Return binary value. 
 
 
 
 Random a number between kmax, kmin inclusively.  
 If k is greater than the current set elements. 
 
Randomly choose gene r from the whole gene set G. 𝑀! = 𝑀! plus gene r 
 
Else if k is less than the current set elements. 
Randomly choose gene r from the whole gene set G. 𝑀! = 𝑀! minus gene r 
Calculate Wi by replacing gene s in set Mi with gene r. 
p is Min between 1 and the weight difference Wi. 
The more p the more likely 𝑀!!!to be equal 𝑀!. 
Go to next iteration with the same set Mi if 𝑀! fail not 
replace Mi. 
	  	   27	  
We run MCMC three times for each disease. Each time the run ends we delete 
all lines that included discovered genes. We wanted to know after that if the 
genes we discovered are drivers. We matched each gene we discovered to the 
following dataset. 
5. Validation of results  
            A significant problem in discovering driver mutations is how to verify 
which are the cancer driver genes, since if we already had a sound method of 
positively discovering this; our current research would be unnecessary. There is 
no solution to this widely known problem, although we do have some methods for 
narrowing the field of candidate drivers down to dataset that most likely to be 
drivers, polymorphism or otherwise unknown.  
5.1 Catalog of Somatic Mutations in Cancer (COSMIC) and whole genome 
(WG) 
            Gonzalez-Perez introduced a method of transformed Functional Impact 
Score, which assesses non-synonymous single nucleotide tolerance of 
variations. The mutations causing the highest functional impact have a high 
probability of being actual cancer drivers. They downloaded all somatic nSNVs 
from COSMIC. Also, they gathered the whole genome (WG) dataset by pooling 
somatic mutations from several sources including the International Cancer 
Genome Consortium (ICGC) Data Coordination Center. The algorithm they used 
results in several subset dataset (Gonzalez-Perez , 2012). We only considered 
three of them. The first dataset is cosmic5.dataset, which is list of somatic 
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mutations that appear in more than 4 Cosmic samples. The second dataset is 
wgCGC.dataset, which is a list of somatic mutations detected by "whole cancer 
genome" projects that occur in known cancer genes. We pooled cosmic5.dataset 
with wgCGC.dataset to get one dataset of known driver somatic mutation genes.  
We tested each list of genes we got from MCMC algorithm against this dataset to 
check if they are drivers. The third file we used is Pol.dataset, list of known 
polymorphisms extracted from the HumVar (a dataset of disease-related SNVs 
and neutral polymorphisms) dataset. We used this dataset to test if the list of 
genes we got are known to be polymorphism. 
5.2 Kyoto Encyclopedia of Genes and Genomes (KEGG) 
            KEGG is a database resource for understanding high-level functions and 
utilities of the biological system, from molecular-level information technologies 
generated by genome sequencing and other high-throughput experimental 
(KEGG, 2013). We extract a list of known cancer genes from KEGG web 
database to be another source of comparing the list of genes we got.  
5.3 Foundation Medicine (FM) 
            We also tested the gene list against a list from Foundation Medicine that 
was gathered by testing 304 patients for solid tumor analyzed by NGS assay 
(Palmer, 2013). 
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5.4 Literature Review  
            We used Google Scholar and PubMed to check on genes that does not 
exist on either of the previous datasets. We wanted to confirm that a given gene 
is not a polymorphism. 
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Chapter 3  
Results and Discussion  
 
            In order to find maximum weight of mutually exclusive set of genes we 
ran our program using MCMC algorithm against three cancer types; 
Glioblastoma Multiforme (GBM), Breast Invasive Carcinoma (BRCA) and Colon 
Adenocarcinoma (COAD). The program was ran three times, following each run 
we had candidate driver genes, therefore we went back to the original dataset 
and delete the genes and rerun the program. The results are described in tables 
where each disease consists of two tables. The first one is the results table from 
the program and the second one is the validation of the results table. In the result 
tables, each row represents a run. The parameter we pass into the program was 
to iterate 100,000 times and to explore set cardinality between 3 and 7 elements 
to improve the weight. In validation of the results tables we gave a value of 1 if a 
given gene exists in that dataset or zero otherwise. The Literature review column 
is a quick review to check if the gene does not exist in any datasets. We wanted 
to confirm that a given gene mutation is not a known polymorphism and that it 
has the potential to be a driver mutation. The last column, which we called 
“unknown” contains a value of 1 if the gene is ambiguous or 0 otherwise. 
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1. Glioblastoma Multiforme (GBM) 
1.1 GBM Results Table (Table 1) 
Weight Gene1 Gene2 Gene3 Gene4 Gene5 Gene6 Gene7 
137 FSD1  TP53 PIGB RNF19A CDADC1 COPB2  
157 HOXD4  PCLO HNRNPA1P7 ENPEP MTMR3 CPNE8 UXS1 
152 ONECUT2  VEPH1 TCHH PLEKHH1 STAG3L3 PPP1R16B  
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1.2 GBM Validation Table 
Gene COSMIC  
Driver 
COSMIC 
Polymorphism 
KEGG Foundation 
Medicine  
Literature 
Reviews  
Unknown 
FSD1 0 0 0 0 (Amandine, 2010) 1 
TP53 1 1 1 1 NA 0 
PIGB 0 0 0 0 0 1 
RNF19A 0 0 0 0 0 1 
CDADC1 0 0 0 0 0 1 
COPB2 0 0 0 0 0 1 
HOXD4 0 0 0 0 0 1 
PCLO 0 0 0 0 0 1 
ENPEP 0 0 0 0 0 1 
MTMR3 0 0 0 0 (Song, 2010) 1 
PNE8 0 0 0 0 0 1 
UXS1 0 0 0 0 0 1 
ONECUT
2 
0 0 0 0 0 1 
VEPH1 0 0 0 0 0 1 
TCHH 0 0 0 0 0 1 
PLEKHH1 0 0 0 0 0 1 
PPP1R16
B 
0 0 0 0 0 1 
 
	  	   33	  
2. Breast Invasive Carcinoma (BRCA) 
2.1 BRCA Results Table 
Weight Gene1 Gene2 Gene3 Gene4 Gene5 Gene6 Gene7 
263 CDH12  TP53 CDH1 NR2F1 ARHGEF3-AS1   
231 NCAM2  SOLH PHF3 EPC1 TRIM58 TNFRSF11B  
243 PIK3CA  ROBO2 DSCR4 CD19 HMCN1 FCN2  
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2.2 BRCA Validation Table 
Gene COSMIC  
Driver 
COSMIC 
Polymorphism 
KEGG Foundation 
Medicine  
Literature 
Reviews  
Unknown 
CDH12 0 1 0 0 (Wang J. , 2011) 1 
TP53 1 1 1 1 NA 0 
CDH1 1 1 0 1 NA 0 
NR2F1 0 0 0 0 (Smits , 2013) 1 
NCAM2 0 0 0 0 (Takahashi, 2011) 1 
SOLH 0 0 0 0 0 1 
PHF3 0 1 0 0 0 0 
EPC1 0 0 0 0 (Matthias , 2010) 1 
TRIM58 0 0 0 0 0 1 
TNFRSF11B 0 1 0 0 NA 0 
PIK3CA 1 0 0 1 NA 0 
ROBO2 0 0 0 0 0 1 
DSCR4 0 0 0 0 0 1 
CD19 0 0 0 0 0 1 
HMCN1 0 1 0 0 0 0 
FCN2 0 0 0 0 0 1 	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3. Colon Adenocarcinoma (COAD) 
3.1 COAD Results Table 
Weight Gene1 Gene2 Gene3 Gene4 Gene5 Gene6 Gene7 
159 TP53  JAKMIP1 ARMCX6 DPP9 DCLK3 ZNF532 C6orf225 
179 APC  SCNN1A GLP2R SDF2L1    
135 SHOX  NCAM2 BHMT2 STAM2 CYSTM1   
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3.2 COAD Validation Table 
Gene COSMIC 
Driver 
COSMIC 
Polymorphism 
KEGG Foundation 
Medicine 
Literature 
Reviews 
Unknown 
TP53 1 1 1 1 NA 0 
JAKMIP1 0 0 0 0 (Okai, 2013) 1 
ARMCX6 0 0 0 0 0 1 
DPP9 0 0 0 0 (Wilson , 2012) 1 
DCLK3 0 0 0 0 0 1 
ZNF532 0 0 0 0 0 1 
C6orf225 0 0 0 0 0 1 
APC 1 1 0 1 NA 0 
SCNN1A 0 0 0 0 (Endoh , 2004) 1 
GLP2R 0 0 0 0 0 1 
SDF2L1 0 0 0 0 0 1 
SHOX 0 0 0 0 (Kneip, 2011) 1 
NCAM2 0 0 0 0 (Wang S. , 1999) 1 
BHMT2 0 0 0 0 0 1 
STAM2 0 0 0 0 0 1 
CYSTM1 0 0 0 0 0 1 
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            By analyzing our results that were obtained by running the program we 
observed 19 candidate genes from GBM, 17 candidate Genes from BRCA and 
16 candidate Genes from COAD. We have divided the Genes into 3 categories:  
4. Discussion  
4.1 Genes identified in the driver datasets 
            For GBM and COAD we did not find any genes from the driver dataset 
exclusively while for BRCA we found PIK3CA as a known driver gene. In 
contrast, we found many genes that appear in both driver and polymorphism 
datasets. For GBM we identified TP53, which is a known tumor suppressor 
gene. For BRCA we were able to identify TP53 and CDH1, the latter of which is 
also known to be a tumor suppressor gene. In COAD we have again TP53 and 
APC, which is also known as a tumor suppressor gene. Having genes in driver 
and polymorphism datasets is not a common finding. One explanation for the 
presence of some genes in both sets is that the COSMIC polymorphism dataset 
has some single nucleotide mutation in the driver genes that does not affect the 
tumor suppression function of the gene. In our TCGA data filtration we only 
considered the gene name instead of taking each single nucleotide mutation for 
two reasons. The first one is that a much bigger data would be needed for the 
analysis of single nucleotide in each gene as each gene could have multiple 
single nucleotide substitutions. The other reason is that we had copy number 
and methylation data, which are different, level data sources and we wanted to 
unify the input data to be gene symbol only. Therefore, we narrowed the search 
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for driver genes into a limited number of genes that needed further investigation 
to exclude them from the polymorphism list. 
4.2 Genes that were found in polymorphism datasets 
            CDH12, PHF3, TNFRSF11B and HMCN1 were genes appearing in the 
polymorphism dataset and they all belong to BRCA. Although, it is reasonable to 
exclude the genes appearing in this dataset as driver, having copy number 
variation as part of our data from TCGA may be due to a deletion in a tumor 
suppressor gene or an amplification of an oncogene that can cause cancer. It is 
also possible that the genes we found in the polymorphism dataset may not be 
excluded as driver genes because driver gene datasets are not exhaustive. 
Knowing these two facts, it is of great importance to investigate further the 
genes in the polymorphism dataset to confirm that they are not driver genes. For 
example CDH12 that found under this category is known of promoting the 
invasion of salivary adenoid cystic carcinoma (Wang J. , 2011).  
4.3 Genes that were not found in either driver or polymorphism datasets 
“unknown” 
            The majority and the rest of the genes occur under this criterion. We 
approach these unknown genes by doing literature review on those genes. The 
purpose of the literature review was to exclude those genes from being a 
polymorphism. We did not find strong evidence that those genes are considered 
a polymorphism. Moreover, we find that some of these “unknown” genes have 
the potential to be driver genes. For example FSD1 methylation has the potential 
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to be a driver gene (Amandine, 2010) in GBM. Another gene MTMR3 in GBM 
plays a role in colon cancer, which makes it a candidate driver gene. On the 
other hand, CDH12 that was found by COSMIC polymorphism dataset promotes 
the invasion of salivary adenoid cystic carcinoma (Wang J. , 2011). Furthermore, 
in COAD JAKMIP1 overexpression has shown an association with cell cancer 
proliferation in vitro (Okai, 2013). This suggests that copy number alterations 
could be the driver gene of cancer and the driver gene lists are not exhaustive. 
5. Future directions 
         It is notable that some of the candidate genes that we obtained from our 
run are considered candidate drivers because we had patients not covered by 
any genes and the set size is flexible. Increasing the set by genes that cover 
even one patient increases the weight of the set, even if those genes are 
mutated only in that one patient. To alleviate this, we may consider limiting the 
set of genes to those above some frequency threshold in the dataset.  
            Large number of genes previously not recognized as drivers may indicate 
the existence of limitations of the utilized method. We expected to have the 
majority of the genes in the driver dataset but found otherwise. The method can 
be improved if we take into account the effect of copy number variation and 
methylation. For example we could only consider copy number variation or 
methylation that has an effect on gene expression 
 
	  	   40	  
References 
	  Amandine,	  E.	  (2010).	  DNA	  methylation	  in	  glioblastoma:	  impact	  on	  gene	  expression	  and	  clinical	  outcome.	  BMC	  Genomics	  ,	  11:701.	  American	  Cancer	  Society.	  (2013).	  Cancer	  Facts	  &	  Figures	  2013.	  Atlanta:	  American	  Cancer	  Society.	  Bertram,	  J.	  S.	  (2000).	  The	  molecular	  biology	  of	  cancer.	  Molecular	  aspects	  of	  medicine	  ,	  167-­‐223.	  Chen-­‐Hsiang,	  Y.	  (2008).	  Combinatorial	  patterns	  of	  somatic	  gene	  mutations	  in	  cancer	  .	  Combinatorial	  patterns	  of	  somatic	  gene	  mutations	  in	  cancer	  ,	  2605–2622.	  Ciriello,	  G.,	  Cerami,	  E.,	  &	  Sander,	  C.	  (2012).	  Mutual	  exclusivity	  analysis	  identifies	  oncogenic	  network	  modules	  .	  Genome	  Res.	  ,	  398-­‐406	  .	  Dawson,	  M.	  A.,	  &	  Kouzarides,	  T.	  (2012).	  Cancer	  Epigenetics:	  From	  Mechanism	  to	  Therapy.	  Cell	  ,	  12-­‐27.	  Endoh	  ,	  H.	  (2004).	  Prognostic	  model	  of	  pulmonary	  adenocarcinoma	  by	  expression	  profiling	  of	  eight	  genes	  as	  determined	  by	  quantitative	  real-­‐time	  reverse	  transcriptase	  polymerase	  chain	  reaction.	  J	  Clin	  Oncol	  ,	  22(5):811-­‐9.	  Gonzalez-­‐Perez	  ,	  A.	  (2012).	  Improving	  the	  prediction	  of	  the	  functional	  impact	  of	  cancer	  mutations	  by	  baseline	  tolerance	  transformation.	  Genome	  Medicine	  ,	  4:89	  .	  Haber,	  D.	  A.,	  &	  Settleman,	  J.	  (2007).	  Cancer:	  Drivers	  and	  passengers.	  Nature	  ,	  145-­‐146.	  Hanahan,	  D.,	  &	  Weinberg,	  R.	  A.	  (2000).	  The	  hallmarks	  of	  cancer.	  Cell	  ,	  57-­‐70.	  Hastings,	  W.	  K.	  (1970).	  Monte	  Carlo	  sampling	  methods	  using	  Markov	  chains	  and	  their	  applications.	  Biometrika	  57	  ,	  97–109.	  KEGG.	  (2013,	  NOV	  28).	  Retrieved	  from	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes:	  http://www.genome.jp/kegg-­‐bin/get_htext?ko00001+K15607	  Kneip,	  C.	  (2011).	  SHOX2	  DNA	  methylation	  is	  a	  biomarker	  for	  the	  diagnosis	  of	  lung	  cancer	  in	  plasma.	  J	  Thorac	  Oncol	  ,	  6(10):1632-­‐8.	  Knudson,	  A.	  G.	  (2002).	  Cncer	  Genetics	  .	  American	  Journal	  of	  Medical	  Genetics	  ,	  96-­‐102.	  Matthias	  ,	  C.	  (2010).	  Down-­‐regulation	  of	  the	  Fetal	  Stem	  Cell	  Factor	  SOX17	  by	  H33342.	  J	  Biol	  Chem	  ,	  6412–6418.	  
	  	   41	  
McCormick,	  F.	  (1999).	  Signalling	  networks	  that	  cause	  cancer.	  Trends	  Cell	  Biol	  9	  ,	  M53–M56.	  Metropolis,	  N.	  (1953).	  Equation	  of	  state	  calculations	  by	  fast	  computing	  machines.	  J	  
Chem	  Phys	  21	  ,	  1087–1092.	  Okai,	  I.	  (2013).	  Overexpression	  of	  JAKMIP1	  associates	  with	  Wnt/beta-­‐catenin	  pathway	  activation	  and	  promotes	  cancer	  cell	  proliferation	  in	  vitro.	  Biomed	  
Pharmacother	  ,	  67(3):228-­‐34.	  Palmer,	  G.	  (2013,	  11	  28).	  http://www.foundationmedicine.com/pdf/posters-­‐
abstracts/FoundationMedicine_2012-­‐06_ASCO_Palmer.pdf.	  Retrieved	  from	  Foundation	  Medicine:	  http://www.foundationmedicine.com/pdf/posters-­‐abstracts/FoundationMedicine_2012-­‐06_ASCO_Palmer.pdf	  Smits	  ,	  B.	  (2013).	  The	  gene	  desert	  mammary	  carcinoma	  susceptibility	  locus	  Mcs1a	  regulates	  Nr2f1	  modifying	  mammary	  epithelial	  cell	  differentiation	  and	  proliferation.	  
PLoS	  Genet	  .	  Song,	  S.	  (2010).	  Mutational	  analysis	  of	  mononucleotide	  repeats	  in	  dual	  specificity	  tyrosine	  phosphatase	  genes	  in	  gastric	  and	  colon	  carcinomas	  with	  microsatellite	  instability.	  APMIS	  ,	  118(5):389-­‐93.	  Takahashi,	  S.	  (2011).	  Neural	  cell	  adhesion	  molecule	  2	  as	  a	  target	  molecule	  for	  prostate	  and	  breast	  cancer	  gene	  therapy.	  Cancer	  Sc	  ,	  102(4):808-­‐14.	  Vogelstein,	  B.,	  &	  Kinzler,	  K.	  W.	  (2004).	  Cancer	  genes	  and	  the	  pathways	  they	  control.	  
NATURE	  MEDICINE	  ,	  789–799	  .	  Wang	  ,	  J.	  (2011).	  CDH12	  promotes	  the	  invasion	  of	  salivary	  adenoid	  cystic	  carcinoma.	  
Oncol	  Rep	  ,	  101-­‐8.	  Wang	  ,	  S.	  (1999).	  Refined	  mapping	  of	  two	  regions	  of	  loss	  of	  heterozygosity	  on	  chromosome	  band	  11q23	  in	  lung	  cancer.	  Genes	  Chromosomes	  Cancer.	  ,	  25(2):154-­‐9.	  Wilson	  ,	  C.	  (2012).	  Expression	  profiling	  of	  dipeptidyl	  peptidase	  8	  and	  9	  in	  breast	  and	  ovarian	  carcinoma	  cell	  lines.	  Int	  J	  Oncol	  ,	  41(3):919-­‐32.	  	  
 
 
 
	  	   42	  
Vita 
Yahya Abdulfattah Bokhari was born on November 29, 1981, in Makkah, Saudi 
Arabia. He graduated from Alshohada high school, Riyadh, Saudi Arabia in 1999. 
He received his Bachelor of Science in Medical Technology Sciences, from King 
Abdulaziz University, Riyadh, Saudi Arabia in 2004 and subsequently worked as 
a medical technologist in a clinical cytogenetics laboratory in King Abdulaziz 
Medical City, Riyadh, Saudi Arabia for four years. In 2008, he obtained the 
American Society Of Clinical Pathology (ASCP) Board of Certification in 
Cytogenetics. On 2008, Yahya received a scholarship from King Abdullah 
Research center to pursue his graduate study in the field of Bioinformatics. He 
joined the Bioinformatics program in Virginia Commonwealth University in 2010. 
 
